Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 15;8(9):682-7.
doi: 10.4251/wjgo.v8.i9.682.

Pancreatic cancer: New hopes after first line treatment

Francesca Aroldi  1 , Paola Bertocchi  1 , Giordano Savelli  1 , Edoardo Rosso  1 , Alberto Zaniboni  1
Affiliations
Review

Pancreatic cancer: New hopes after first line treatment

Francesca Aroldi et al. World J Gastrointest Oncol. .

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Extensive research has yielded advances in first-line treatment strategies, but there is no standardized second-line therapy. In this review, we examine the literature trying to establish a possible therapeutic algorithm.

Keywords: Algorithm; Nab-paclitaxel; Nal-iri; Pancreatic cancer; Second line.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they do not have any conflict of interest.

Figures

Figure 1
Figure 1
Proposed algorithm of pancreatic cancer therapy. 5-FU: 5-fluorouracil; LLV: L-leucovorin.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
    1. Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C, Parthenaki I. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J Gastrointest Cancer. 2015;46:201–211. - PMC - PubMed
    1. National Comprehensive Cancer Network. NCCN pancreatic guideline. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
    1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413. - PubMed
    1. Smyth EN, Bapat B, Ball DE, André T, Kaye JA. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clin Ther. 2015;37:1301–1316. - PubMed

LinkOut - more resources